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Background: Italian consensus for the classification and reporting of thyroid cytology
(ICCRTC) has been used in almost all Italian institutions since 2014. High reliability
of ICCRTC in classifying low and high risk indeterminate nodules (Tir 3A and Tir 3B,
respectively) was demonstrated. Here we reviewed our casuistry of thyroid indeterminate
lesions to analyze the histologic outcome.
Methods: All lesions undergone FNA and final histology at S. Andrea Hospital of Rome
after a cytologic assessment of Tir 3A and Tir 3B, according to ICCRTC, were included
in the study.
Results: A number of 157 indeterminate FNA was found after the introduction of
ICCRTC. Of these, 75 undergone surgery and were finally included for the study. At
histology we found a 33.3% of cancers and a 67.7% of benign lesions. Out of the overall
series, 25 were classified as Tir 3A and 50 as Tir 3B. Cancer rate observed in Tir 3A (1/25,
4%) was significantly (p = 0.0002) lower than that of Tir 3B (24/50, 48%). No significant
difference was found in age and size between the two subcategories.
Conclusions: We confirm in our series that Italian consensus for the classification and
reporting of thyroid cytology allows to discriminate indeterminate lesions at low and high
risk of malignancy.
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INTRODUCTION
Cytology from fine-needle aspiration (FNA) is recognized as the pivotal evaluation of thyroid
nodules to detect malignancy and benign lesions (1, 2). The most significant limit of FNA is
represented by indeterminate cytologic report which occurs in up to 20–25% of all FNA. Out
of these cases, only a rate of one in four or one in three is expected to be a cancer at final
histology. Thus, to preoperatively diagnose thyroid nodules cytologically classified as indeterminate
has represented one major challenge (3). Even if many imaging or molecular parameters have been
investigated (4–14), none has reached the final evidence to be used in clinical practice.
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During the last years the most important international
societies have revised their guidelines for reporting thyroid
cytology in the attempt to discriminate indeterminate lesions at
high risk of malignancy and that at low risk, in which surgery
or clinical follow-up should be considered, respectively (15, 16).
More recently, the Italian consensus for the classification and
reporting of thyroid cytology (ICCRTC) reported a five-classes
system with a subclassification of Tir 3 in Tir 3A (low risk) and
Tir 3B (high risk) (17). In the Italian system, Tir 3A is defined
as increased cellularity with numerous microfollicular structures
in a background of scant colloid; this category also includes
partially compromised samples such as preparation artifacts or
blood contamination; on the other hand Tir 3B is featured
by high cellularity in a monotonous microfollicular/trabecular
arrangement, with scant or absent colloid, suggestive for
follicular neoplasm (3); furthermore, ICCRTC includes in the
subcategory Tir 3B those cases with “mild/focal nuclear atypia,”
while British and Bethesda classifications include the atypia in
their categories of indeterminate at low risk [i.e., Thy 3a (15) and
Category III (16), respectively]. Importantly, relevant findings
were found in a meta-analysis on the reliability of ICCRTC to
select high and low risk lesions, being the rate of malignancy of
Tir 3A significantly lower than that of Tir 3B (18).
At our institute the most updated version of Italian system
for reporting thyroid cytology (17) has been used since its
publication, and the patients have been managed according
to these reports. The above mentioned interesting results of
ICCRTC (18) prompted us to review our series of indeterminate
nodules and verify these data.
MATERIALS AND METHODS
Selection of Patients
We initially searched in our database all nodules cytologically
classified as indeterminate after the systematic introduction of
ICCRTC at our institute (December 2014) and the last search was
performed on 30 April 2018. Then, we selected for the present
study only lesions undergone both FNA and final histology at our
institutes. At our institute, thyroid nodules with indeterminate
FNA report are generally addressed to surgery in presence of
ultrasound or clinical features suspicious for malignancy or when
they are within a large goiter with compressive symptoms. The
study was approved by Ethical Committee of Ospedale S. Andrea
of Rome.
Gold Standard of the Study
Histologic diagnosis was adopted as gold standard in all cases.
Statistical Analysis
The prevalence of cancers among the categories Tir 3A and
Tir 3B was compared by chi square or Fisher exact test,
when indicated. Continuous variables (such as patients’ age and
nodules’ size) were compared byMann-Whitney non-parametric
test. Incidentally discovered cancers (i.e., microcarcinomas found
in another nodule) were not considered for statistical analysis.
Statistical significance was set at p = 0.05. All statistical analyses
were performed by MedCalc (MedCalc Software bvba, Belgium).
RESULTS
According to the selection criteria a number of 157 nodules
with indeterminate FNA, of which 58 Tir 3A and 99 Tir 3B
was initially found in our registry. After exclusion of those
cases not yet resected (n = 82), a series of 75 indeterminate
lesions from 71 patients (46 female, 25 male, mean age was
52 year) were included as study series. At final histology 25
(33.3%) carcinomas and 50 (67.7%) benign lesions were found.
No significant difference (p = 0.48) was found in cancer rate
between females (20/46, 43.4%) and males (8/25, 32%). The
mean age in the cancer group did not significantly differ from
that of benign group (mean age 52 yr in both). No significant
difference was found in mean nodules’ size being 19.6mm in
cancers and 22.7mm in benign lesions. Table 1 details features
of the series.
When we analyzed the subcategories of low and high risk,
we found 25 nodules classified as Tir 3A and 50 as Tir 3B.
As a significant difference, the cancer rate observed in Tir 3A
(1/25, 4%) was significantly (p = 0.0002) lower than that of
Tir 3B (24/50, 48%) (Figure 1). No significant differences were
found in the age and size between the two subcategories. Among
the malignant lesions, 21 papillary carcinomas (all in Tir 3B
group), 2 follicular carcinomas (1 in Tir 3B and 1 in Tir 3A),
and 2 medullary carcinomas (all in Tir 3B). In the latter cases
calcitonin value was not available at the moment of cytologic
examination. Table 2 reports details of histologic type/subtype of
cancers and ATA risk assessment of differentiated ones. Between
the benign lesions there were 10 follicular adenomas (4 in Tir 3B
and 6 in Tir 3A), 9 oncocytic adenomas (7 in Tir 3B and
2 in Tir 3A), 20 adenomatous hyperplasias (11 in Tir 3B and
9 in Tir 3A), and 9 thyroiditis hyperplasias (4 in Tir 3B and 5
in Tir 3A).
DISCUSSION
The major challenge of current international guidelines for
thyroid cytology (15–17) is the discrimination of nodules with
indeterminate pattern at low and high risk of malignancy. This
issue is crucial to address patients to surgical resection when they
have a high risk (Tir 3B, Thy 3f, Category IV) or to clinical and
ultrasonographic follow-up in presence of low risk (Tir 3A, Thy
3a, Category III). The most recent literature has showed that
TABLE 1 | Main characteristic of the series.
Nodule/patients with histologic outcome (n) 75 nodules/71 patients
Females/males (n) 46/25
Mean age (yr) 52.3
Tir 3B/Tir 3A (n) 50/25
Mean size of nodules (mm) 21.2
Cancers/benign lesions at histology (n) 25/50
The final series of 75 lesions with histologic follow-up was collected among a series of
157 cases with indeterminate FNA recorded during the study period.
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FIGURE 1 | Percentage of malignant nodules recorded in 75 thyroid nodules cytologically classified as Tir 3A (low risk) or Tir 3B (high risk).
TABLE 2 | Histologic type and ATA risk assessment of differentiated carcinomas
of the series.
Tir 3A Tir 3B
Histologic type of carcinomas (n)
Follicular variant of papillary carcinoma – 12
Classic variant of papillary carcinoma – 6
Oncocytic variant of papillary carcinoma – 2
Poorly differentiated carcinoma – 1
Follicular carcinoma 1 1
Medullary carcinoma – 2
ATA risk class of differentiated carcinomas (n)
Low risk 1 14
Intermediate risk – 8
High risk – 2
The final series of cancer included 23 differentiated carcinomas and 2 medullary
carcinomas. Risk assessment was made according to ATA guidelines (2).
ICCRTC (17) can play a significant role in managing patients
with indeterminate FNA report due to optimal performance
to assess these lesions at low and high risk (18). The results
of that meta-analysis (18) were obtained by pooling data from
studies including nodules re-classified retrospectively according
to ICCRTC (19–24). However, similar results were recorded later
in papers including nodules prospectively classified according
to ICCRTC (25, 26). Our present data, recorded in a series of
indeterminate nodules entirely classified by ICCRTC during the
clinical practice, corroborate that previously observed by the
other Italian and Switzerland institutes (19–26). Figures 2, 3
illustrate the cytologic presentation of two cases of the series. In
fact, a significant difference of cancer rate was observed between
Tir 3A and Tir 3B. As a strength of the present findings, the rate
of malignancy of the overall series (33.3%) was in line with that
FIGURE 2 | One centimeter solid hypoechoic thyroid nodule in a 65 year old
woman cytologically classified as Tir 3A. Follicular proliferation on a bloody
background (400X).
one would expect in a group of indeterminate thyroid nodules
undergone surgery (Figure 1). On the other hand, the different
cancer rate reported in different institutes (19–26) reflects the
specific institutional approach to indeterminate lesions; low
cancer rate should depend on a high percentage of patients
submitted to surgery. Following the present data and the above
published papers (19–26), ICCRTC has to be considered as
reliable to manage indeterminate lesions in the clinical practice.
In this context, no high reliability of the Bethesda system (16)
was recorded in a meta-analysis, and significant difference was
reported by Rullo et al. (27) in a large series of indeterminate
nodules retrospectively re-classified according to both ICCRTC
(17) and Bethesda system (16); there, the rate of malignancy in
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FIGURE 3 | Mixed hypoechoic thyroid nodule 1.5 cm in major diameter in a 72
year old woman cytologically classified as Tir 3B. A follicle with focal nuclear
clearing on a mixed colloid and hematic background (1000X).
the AUS-FLUS (category III) was significantly higher than in Tir
3A, while there were no differences between FN/SFN (category
IV) and Tir 3B. In addition, suboptimal performance of Bethesda
system was recorded in a previous meta-analysis combining
large series of studies with nodules classified as Category III or
IV (28). These limits of the Bethesda system should be solved
by its revised version (29). This issue indirectly supports the
rationale of ICCRTC 2014 (17) and advices for new papers and
new meta-analyses to further evaluate the cancer risk of the
categories III and IV. All in all, the excellent performance of
ICCRTC in identifying low and high risk indeterminate lesions
could reach a significant interest for clinical practice, especially
in patients with low risk who may be followed-up over time
(30).
Some potential limits of the present study should be discussed.
Present data report a series of 75 nodules undergone final
diagnostic surgery among a large series of 157 cases with
indeterminate FNA report; this study design could introduce a
selection bias and then reduce the statistical strength of results.
On the other hand, all cases included in the final series had
been prospectively classified as Tir 3A or Tir 3B by pathologists
with large experience of more than 20 years and managed by
clinicians consequently. Certainly, other clinical features might
have influenced the decisional planning of surgical treatment. A
prospective multicenter trial remains the optimal study design in
this context.
In conclusion, the present study confirms that the ICCRTC
guidelines discriminate efficiently indeterminate lesions at low
risk of malignancy from those at high risk and could be used
confidentially in clinical practice.
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